Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acino

- PMLiVE

Shire claims FDA approval for slow-cooked ADHD drug

Mydayis will reach the US market in the third quarter of the year

- PMLiVE

Shire licences Parion dry eye drug in $535m deal

Bolsters the Irish group's ophthalmic portfolio

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

- PMLiVE

Private equity firms agree deal to take over Stada

Cinven and Bain Capital beat out competition from Advent International

National Institute for Health and Care Excellence NICE logo

NICE knocks-back Shire’s pancreatic cancer drug Onivyde

Final guidance rules it's not a cost-effective use of NHS resources

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

Stada confirms Cinven as one of two takeover bidders

Private equity group offers €3.6bn for the generics and over-the-counter medicines manufacturer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links